Streetbeat News

Revenues

GE

Eight analysts have recently updated their ratings on General Electric (NYSE:GE), showing a mix of bullish and somewhat bullish sentiments, with an average 12-month price target of $151.0, up from $137.00. The ratings adjustments reflect analysts' responses to GE's market performance and company developments. GE's financials indicate strong growth, profitability, and effective debt management, with a notable market capitalization, revenue growth of 15.43%, a net margin of 8.2%, ROE of 5.68%, and ROA of 1.0%. The company's strategic positioning and financial health are highlighted as key factors in its market performance.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 4:01 pm

NARI

Inari Medical (NASDAQ:NARI) has seen diverse analyst ratings over the past quarter, with recent actions including maintaining, lowering, and raising ratings and price targets. The average 12-month price target is now $67.5, down from $73.00, indicating a 7.53% decrease. Inari Medical's financial performance shows strong growth and profitability, with a revenue growth rate of 31.35% as of September 30, 2023, and a net margin of 2.5%. The company's ROE and ROA exceed industry averages, and it maintains a low debt-to-equity ratio of 0.07.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 4:01 pm

MRSN

Mersana Therapeutics (NASDAQ:MRSN) received mixed ratings from 5 analysts, with a notable upward trend in the 12-month price target to $6.6, reflecting a 103.08% increase from the previous target of $3.25. Analysts' actions include raises and maintains, with price targets ranging from $5.00 to $9.00. The company's financial performance shows substantial revenue growth and efficient cost management, despite challenges in ROE, ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 4:00 pm

CTAS

Analyst ratings for Cintas (NASDAQ:CTAS) show a mix of bullish to bearish sentiments, with recent updates indicating a positive trend. The average 12-month price target is $637.86, reflecting a 10.47% increase from the previous target. Analysts from firms like Barclays, Truist Securities, and JP Morgan have raised their price targets, citing the company's strong financial performance, including a 9.3% revenue growth and a net margin of 15.7%. Cintas's market position is strengthened by its diverse offerings in uniform rental, facility services, and safety products.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 4:00 pm

HLLY

Holley (NYSE:HLLY) was analyzed by 4 analysts, showing a mix of bullish to indifferent sentiments with no bearish views. The average 12-month price target is $7.75, with a high of $9.00 and a low of $5.00. Analyst actions include both maintaining and lowering ratings, with price targets adjusted accordingly. Holley, a designer and manufacturer of high-performance automotive aftermarket products, shows positive revenue growth but faces challenges in profitability, debt management, and capital utilization.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:01 pm

MQ

In the past three months, Marqeta (NASDAQ:MQ) received varied analyst ratings, with a recent shift towards more bullish perspectives. The average 12-month price target for MQ is now $8.00, up from $7.25, indicating a positive outlook. Analysts from firms like Truist Securities and Barclays have adjusted their ratings and price targets, reflecting optimism about Marqeta's future performance despite its current financial challenges, including a significant revenue decline and below-average profitability metrics.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:01 pm

ADMA

Analyst ratings for ADMA Biologics (NASDAQ:ADMA) show a mix of bullish to bearish sentiments, with a recent trend towards more bullish projections. The average 12-month price target is now $6.75, up from $6.00, indicating a positive outlook. Key financial indicators reveal strong revenue growth, profitability, and financial health, despite a high debt-to-equity ratio. The company specializes in plasma-derived biologics for immunodeficient patients.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:01 pm

ALKT

Alkami Technology (NASDAQ:ALKT) received mixed analyst ratings with an average 12-month price target of $27.12, reflecting a 17.05% increase from the previous target. The company showed a revenue growth of 26.76% as of September 30, 2023, but struggles with a net margin of -22.86% and an ROA of -3.24%. Despite these challenges, Alkami's ROE outperforms industry averages at -4.8%, and it maintains a low debt-to-equity ratio of 0.32.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:00 pm

ACMR

ACM Research (NASDAQ:ACMR) has seen varied analyst ratings over the past three months, with a recent shift towards more bullish perspectives. The average 12-month price target for ACMR has been raised to $28.02, marking a 23.44% increase from the previous target. Analysts from Benchmark, Needham, Goldman Sachs, Roth MKM, and Needham have adjusted their ratings and price targets, reflecting optimism about ACMR's market position and financial health. The company's revenue growth, net margin, ROE, ROA, and debt management are highlighted as key financial strengths.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:00 pm

BLBD

Blue Bird (NASDAQ:BLBD) received mixed analyst ratings with 3 bullish and 1 somewhat bullish in the past three months. The average 12-month price target is $38.0, reflecting a 34.13% increase from the previous $28.33. Analysts from Needham, Barclays, Roth MKM, and Craig-Hallum have adjusted their ratings and price targets, indicating a positive outlook based on Blue Bird's financial performance, including a notable revenue growth of 34.75%, a net margin of 8.23%, and an ROE of 45.25%. However, the company's debt-to-equity ratio of 1.8 suggests higher financial risk.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 3:00 pm